Kim SG, Seo HS, Lee HH, Song KY, Park CH. Comparison of the differences in survival rates between the 7th and 8th editions of the AJCC TNM staging system for gastric adenocarcinoma: a single-institution study of 5,507 patients in Korea. J Gastric Cancer. 2017;17:212–9.

Article  PubMed  PubMed Central  Google Scholar 

Nashimoto A, et al. Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric Cancer. 2013;16:1–27.

Article  PubMed  Google Scholar 

Nakajima T, et al. Combined intensive chemotherapy and radical surgery for incurable gastric cancer. Ann Surg Oncol. 1997;4:203–8.

Article  CAS  PubMed  Google Scholar 

Terashima M. Conversion therapy for gastric cancer: who can make conversion as successful as Goromaru? Gastric Cancer. 2016;19:685–6.

Article  PubMed  Google Scholar 

Sumpter K, et al. Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer. 2005;92:1976–83.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Qin S, et al. Treatment patterns and outcomes in Chinese patients with gastric cancer by HER2 status: a noninterventional registry study (EVIDENCE). Oncologist. 2021;26:e1567–80.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lei Z, et al. Hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis: a multicenter propensity score-matched cohort study. Chin J Cancer Res. 2020;32:794–803.

Article  PubMed  PubMed Central  Google Scholar 

Razenberg LGEM, et al. Trends in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of synchronous peritoneal carcinomatosis of colorectal origin in the Netherlands. Eur J Surg Oncol. 2015;41:466–71.

Article  CAS  PubMed  Google Scholar 

Lei Z, et al. Evaluation of cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for stage III epithelial ovarian cancer. JAMA Netw Open. 2020;3:e2013940.

Article  PubMed  PubMed Central  Google Scholar 

Chalabi M. Stomach cancer gets a triple punch of therapy. Nature. 2021;600:608–9.

Article  CAS  PubMed  Google Scholar 

Wang DY, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4:1721–8.

Article  PubMed  PubMed Central  Google Scholar 

Li Y, et al. Chinese expert consensus on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancies. World J Gastroenterol. 2016;22:6906–16.

Article  PubMed  PubMed Central  Google Scholar 

Wang Z, Chen J-Q. Imaging in assessing hepatic and peritoneal metastases of gastric cancer: a systematic review. BMC Gastroenterol. 2011;11:19.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fujitani K, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016;17:309–18.

Article  CAS  PubMed  Google Scholar 

Ross P, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol. 2002;20:1996–2004.

Article  CAS  PubMed  Google Scholar 

Verwaal VJ. Long-term results of cytoreduction and HIPEC followed by systemic chemotherapy. Cancer J. 2009;15:212–5.

Article  PubMed  Google Scholar 

Yan TD, et al. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol. 2007;14:2702–13.

Article  PubMed  Google Scholar 

Yu P, et al. Hyperthermic intraperitoneal chemotherapy (HIPEC) plus systemic chemotherapy versus systemic chemotherapy alone in locally advanced gastric cancer after D2 radical resection: a randomized-controlled study. J Cancer Res Clin Oncol. 2023;149.

Ishigami H, et al. Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial. J Clin Oncol. 2018;36:1922–9.

Article  CAS  PubMed  Google Scholar 

Los G, et al. Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res. 1989;49:3380–4.

CAS  PubMed  Google Scholar 

Tsimberidou AM, et al. Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis. Hepato-gastroenterology. 2012;59.

Ströhlein MA, Heiss MM, Jauch K-W. The current status of immunotherapy in peritoneal carcinomatosis. Expert Rev Anticancer Ther. 2016;16:1019–27.

Article  PubMed  Google Scholar 

Janjigian YY, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kang Y-K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461–71.

Article  CAS  PubMed  Google Scholar 

Eto S, et al. Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection. Gastric Cancer. 2016;19:466–71.

Article  CAS  PubMed  Google Scholar 

Tamura S, et al. Intraperitoneal administration of paclitaxel and oral S-1 for a patient with peritoneal dissemination and hydronephrosis due to advanced gastric cancer.

Yamaguchi H, et al. A patient with gastric cancer with peritoneal carcinomatosis treated with intraperitoneal chemotherapy who survived more than 5 years receiving repeated laparoscopic examinations: a case report. 2016.

Tazawa H, et al. A case of advanced gastric cancer with peritoneal metastasis treated successfully with nivolumab. Case Rep Oncol. 2019;12:523–8.

Article  PubMed  PubMed Central  Google Scholar 

Meguro Y, et al. Pathological complete response after intraperitoneal paclitaxel and systemic combined chemotherapy in a patient with peritoneal metastases from gastric cancer: a case report. Surg Case Rep. 2020;6:63.

Toyota S, et al. Successful conversion surgery following chylous ascites after nivolumab for advanced gastric cancer. In Vivo. 2020;34:583–5.

Article  PubMed  PubMed Central  Google Scholar 

Kuhara Y, et al. A long-term survival case of unresectable gastric cancer with multidisciplinary therapy including immunotherapy and abscopal effect. Int Canc Conf J. 2020;9:193–8.

Article  Google Scholar 

Duarte Mendes A, Vicente R, Fernandes M, Silva M. Hyperthermic intraperitoneal chemotherapy in gastric cancer: a clinical case involving long-term survival. Cureus. 2023. https://doi.org/10.7759/cureus.45302.

Article  PubMed  PubMed Central  Google Scholar 

Liang S, et al. Camrelizumab and apatinib combined with chemotherapy in perioperative effective therapy for advanced gastric carcinoma with peritoneal metastasis: a case report. J Gastrointest Oncol. 2023;14:2658–67.

Article  PubMed  PubMed Central  Google Scholar 

Murokawa T, et al. Favorable outcome of repeated salvage surgeries for rare metastasis to the ligamentum teres hepatis and the upper abdominal wall in a stage IV gastric cancer patient. Acta Med Okayama. 2023;77.